The 15 references in paper V. Omelyanovskiy V., В. Омельяновский В. (2015) “Готова ли Россия для внедрения национальной системы референтного ценообразования // IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM?” / spz:neicon:pharmacoeconomics:y:2014:i:4:p:36-41

1
Adamyan N.V., Bazhenova A.V. Otsenka i vybor. 2011; 3: 39-43.
(check this in PDF content)
2
Changes from 22.12.2014 N 429-FZ of the law «On Circulation of Medicines» N 61-FZ [Izmeneniya ot 22.12.2014 N 429-FZ v zakon «Ob obrashchenii lekarstvennykh sredstv» N 61-FZ].
(check this in PDF content)
3
Omel'yanovskii V.V., Fedyaeva V.K., Rebrova O.Yu. Guidelines on the application of multi-criteria analysis in health care. Expert Health Council of the Federation Council Committee on Social Policy. Research Institute of Finance Ministry of Finance [Metodicheskie rekomendatsii po primeneniyu mnogokriterial'nogo analiza v zdravookhranenii. Ekspertnyi sovet po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial'noi politike. Nauchno-issledovatel'skii finansovyi institut Ministerstva finansov RF. 2014].
(check this in PDF content)
4
Fedyaev D.V., Maksimova L.V., Omel'yanovskii V.V. Otsenka i vybor. 2014; 1: 57-64.
(check this in PDF content)
5
Diaby V., Campbell K., Goeree R. Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. Operations Research for Health Care. 2013; 2 (1): 20-24.
(check this in PDF content)
6
Drummond M., Jönsson B., Rutten F., Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 2011; 12 (3): 263-71.
(check this in PDF content)
7
Dylst P., Vulto A, Simoens S. Reference pricing systems in Europe: characteristics and consequence. Generics and Biosimilars Initiative Journal. 2012;1:127-31.
(check this in PDF content)
8
Dylst P., Vulto A., Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 2011; 11: 729-37.
(check this in PDF content)
9
European Generic medicines Association. 2011 Market Review. Brussels, Belgium: European Generic medicines Association. 2011.
(check this in PDF content)
10
Federal Joint Comittee. Reference prices and how they are set [Internet]. Fed. Jt. Com. Ger. [cited 2014 Oct 15].
(check this in PDF content)
11
Folino-Gallo P., Muscolo L., Vogler S., Morak S. PHIS Glossary: Glossary for pharmaceutical policies/systems developed in the Pharmaceutical Health Information System (PHIS) Project 2011. issued 2009, updated 2010 and 2011; Commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health in the framework of the Pharmaceutical Health Information System Project. Available from: http://whocc.goeg.at/Publications/ Methodology.
(check this in PDF content)
12
Huttin C. Chapter 8: Experiences with reference pricing. Drugs Money – Prices Affordabil. Cost Contain. Part II Sel. Exp. Policy Options [Internet]. World Health Organization. 2003 [cited 2014 Oct 20]. Available from: http://apps.who.int/medicinedocs/en/d/ Js4912e/3.3.html.
(check this in PDF content)
13
Kanavos P., Reinhardt U.. Reference pricing for drugs: is it compatible with U.S. health care? Health Aff. (Millwood). 2003; 22 (3): 16-30.
(check this in PDF content)
14
López i Casasnovas G., Jonsson B. Universitat Pompeu Fabra, Centre de Recerca en Economia i Salut. Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Barcelona. 2001.
(check this in PDF content)
15
Vrijens F., Van de Voorde C., Farfan-Portet M-I., le Polain M., Lohest O. The reference price system and socio-economic differences in the use of cheap medicines. Brussels, Belgium: KCE; 2010. Report No.: 126A. IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM?
(check this in PDF content)